Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Strategy Aktie 1465124 / US5949724083

28.10.2025 14:30:02

Bitcoin Obsession Costs Saylor — S&P Tags Strategy As ‘Junk’

Strategy Inc., the company led by Michael Saylor that rebranded from MicroStrategy, was hit with a junk credit grade on Monday as S&P Global Ratings flagged its heavy concentration in Bitcoin and weak dollar liquidity.According to S&P, the firm’s balance sheet is tied closely to the price of Bitcoin and carries risks that traditional ratings models find hard to treat as stable collateral.Bitcoin Holdings Drive The ScoreBased on reports, Strategy’s Bitcoin stack is enormous — about 640,808 BTC on its books — worth roughly $73 billion to $74 billion at recent prices.S&P said that while the company owns a large digital-asset hoard, the volatility of that asset and the company’s limited cash flow make it risky under S&P’s credit rules.S&P assigned a B- issuer credit rating and kept the outlook stable. That B- places the company squarely in non-investment-grade territory, signaling a higher chance of stress if markets turn against it.S&P Global Ratings has assigned Strategy Inc a ‘B-‘ Issuer Credit Rating (Outlook Stable) — the first-ever rating of a Bitcoin Treasury Company by a major credit rating agency. https://t.co/WLMkFqkkCb— Michael Saylor (@saylor) October 27, 2025Currency Mismatch And Debt PressureReports have disclosed that S&P was particularly concerned about a mismatch: most obligations are owed in US dollars, but most of the company’s value sits in Bitcoin. This gap can force the sale of Bitcoin to meet dollar payments if prices slide.Analysts and commentators pointed to sizable convertible securities and preferred-stock commitments that add cash demands on the company. According to filings and market write-ups, the firm faces billions of dollars in convertible and preferred obligations spread over coming years.Saylor and Strategy have made repeat purchases of Bitcoin as part of their stated plan. Those buys have created big unrealized gains on paper, but S&P’s methodology largely treats the token differently from traditional equity when measuring risk-adjusted capital.Liquidity, Access To MarketsS&P noted that, for now, Strategy still has access to capital markets, which is why its outlook is stable rather than immediately negative.But the rating agency warned that a sharp drop in Bitcoin’s price or any sudden tightening of funding channels could trigger a further downgrade.Market participants will watch funding costs, preferred dividend payments and convertible notes for signs of stress.Investors reacted with mixed signals in early trading. Some buyers treated the downgrade as a formal recognition of a known risk, while others judged the move as a calibration that won’t stop Saylor’s accumulation strategy if markets stay calm.Trading volume and price swings in both Strategy shares and Bitcoin may rise as traders reassess odds.Featured image from Gemini, chart from TradingViewWeiter zum vollständigen Artikel bei NewsBTC

Analysen zu Strategy (ex MicroStrategy)

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall

Im BX Morning Call spricht die Schweizer Unternehmer-Ikone Etienne Jornod (OM Pharma) mit François Bloch und Olivia Hähnel (BX Swiss) über Führung, Wachstum, Kooperationen, seine Zeit bei der NZZ und darüber, warum Zuhören der wichtigste Leadership-Skill ist.

Die perfekte Folge für alle, die sich für Pharmastrategien, Galenica/Vifor und Unternehmertum interessieren.

🎯 Themen im Interview mit Etienne Jornod (OM Pharma)

– Antrieb und Führungsphilosophie eines Unternehmers
– Erfolgsweg von Galenica – Lehren aus Jahrzehnten Führung
– Frauenquote, Teamkultur und Leadership bei OM Pharma
– Internationale Expansion: China, USA und neue Märkte
– Forschung, Druck und Verantwortung in der Pharmaindustrie
– Inspiration, Balance und persönliche Haltung zum Erfolg
– Zukunftsvisionen: Schweiz, Unternehmertum und Investments

👉🏽 https://bxplus.ch/bx-musterportfolio/

Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’823.22 19.56 S2S3VU
Short 13’094.83 13.71 UEBSLU
Short 13’580.05 8.95 UJOBSU
SMI-Kurs: 12’314.10 29.10.2025 17:31:05
Long 11’736.05 18.56 SHFB5U
Long 11’507.12 13.87 BIYSFU
Long 11’008.02 8.95 BMQS4U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Strategy am 28.10.2025

Chart